Holen Sie sich die Stockscreener-App
17.49
4.01%
-0.73
Handel nachbörslich:
17.70
0.21
+1.20%
Schlusskurs vom Vortag:
$18.22
Offen:
$17.78
24-Stunden-Volumen:
3.40M
Relative Volume:
0.87
Marktkapitalisierung:
$12.99B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-746.08M
KGV:
-17.36
EPS:
-1.0074
Netto-Cashflow:
$-211.81M
1W Leistung:
-9.05%
1M Leistung:
-18.39%
6M Leistung:
-37.31%
1J Leistung:
-12.37%
1-Tages-Spanne:
$17.37
$18.13
1-Wochen-Bereich:
$17.37
$19.34
52-Wochen-Spanne:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.49 | 13.56B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
What institutional flow reveals about Summit Therapeutics Inc.Swing Trade & Smart Investment Allocation Tips - newser.com
Summit Therapeutics (SMMT) Is Down 6.4% After $513M Shelf Filing and Ivonescimab Clinical Updates—Has The Bull Case Changed? - Yahoo Finance
News impact scoring models applied to Summit Therapeutics Inc.Trade Signal Summary & Daily Technical Forecast Reports - newser.com
A Look at Summit Therapeutics (SMMT) Valuation Following Positive HARMONi Trial Results and Regulatory Progress - Yahoo Finance
Is Summit Therapeutics Inc. showing signs of accumulation2025 Geopolitical Influence & Stepwise Swing Trade Plans - newser.com
What MACD and RSI say about Summit Therapeutics Inc.2025 Short Interest & Accurate Technical Buy Alerts - newser.com
Can Summit Therapeutics Inc. hit a new high this monthJuly 2025 Trends & Community Consensus Picks - newser.com
Is Summit Therapeutics Inc. stock reversal real or fakeMarket Trend Report & Weekly Market Pulse Alerts - newser.com
1 Monster Stock in the Making to Buy and Hold - AOL.com
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Insiders Are Snapping Up These 2 Stocks — and Analysts Like What They See - Yahoo Finance
Should you hold or exit Summit Therapeutics Inc. now2025 Volume Leaders & High Conviction Investment Ideas - newser.com
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 - Business Wire
Applying sector rotation models to Summit Therapeutics Inc.2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - newser.com
Summit Therapeutics (SMMT) Aims for FDA Nod for Ivonescimab in N - GuruFocus
Jefferies Cuts Summit Therapeutics (SMMT) Price Target, Keeps Buy Rating - Insider Monkey
Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025 - Insider Monkey
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
13 Stocks to Buy with Exponential Growth Heading into 2026 - Insider Monkey
10 Stocks Under $20 to Buy According to Analysts - Insider Monkey
Summit Therapeutics (SMMT) files for 26.68M share offering by selling stockholders - StreetInsider
Why Wall Street Is Backing These 3 Comeback Stocks - Investing.com
Patterns Watch: Is Summit Therapeutics Inc. stock a safe haven asset2025 Volume Leaders & Weekly High Return Stock Forecasts - fcp.pa.gov.br
Co-CEO & Executive Chairman of Summit Therapeutics Picks Up 2.5% More Stock - simplywall.st
Co-CEO & Executive Chairman of Summit Therapeutics Robert Duggan Buys 2.5% More Shares - Yahoo Finance
Insider Spends US$262m Buying More Shares In Summit Therapeutics - 富途牛牛
Can Summit Therapeutics Inc. stock outperform in 2025 bull marketEarnings Overview Summary & Real-Time Volume Analysis Alerts - Fundação Cultural do Pará
Analyzing Summit Therapeutics Inc. with risk reward ratio charts2025 Price Targets & High Return Stock Watch Alerts - newser.com
Allianz Asset Management GmbH Decreases Stock Holdings in Summit Therapeutics PLC $SMMT - MarketBeat
What margin trends mean for Summit Therapeutics Inc. stock2025 Top Decliners & Fast Exit/Entry Strategy Plans - fcp.pa.gov.br
Summit Therapeutics proves InvestingPro’s Fair Value accuracy with 40% return By Investing.com - Investing.com South Africa
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):